Contact this Provider:
- Endocrinology
- abnormal glucose metabolism
- achondroplasia
- addison's disease
- adrenal adenoma
- adrenal atrophy Show All
- bioidentical hormone replacement therapy
- diabetes education
- fine needle aspiration of thyroid
- insulin pump
- radioiodine therapy Show All
Jean Y. Park, MD is an endocrinologist at MedStar Good Samaritan Hospital and a practicing physician with MedStar Medical Group since 2007. Dr. Park has a special interest in treating diabetes, thyroid disorders, adrenal disorders and pituitary diseases of patients 18 years of age and older.
Dr. Park has been awarded Recognition by the National Committee for Quality Assurance and American Diabetes Association Diabetes Recognition Program (DRP). Clinicians who achieve DRP Recognition are part of an elite group that is publicly recognized for its skill in providing the highest level of diabetes care.
Dr. Park has a role in clinical and research aspects of diabetes, diabetes related conditions, obesity and prediabetes. Her research focuses on optimal treatments for diabetes and prediabetes.
- Fellowship Program: National Institute of Health (2007)
- Residency Program: Robert Wood Johnson University Hospital (2004)
- Internship Program: University of Medicine & Dentistry of NJ RWJ Hosp (2002)
- Medical School: Robert Wood Johnson Medical School (2001)
- Board Certification: American Board of Internal Medicine, Endocrinology Diabetes and Metabolism
Pittas AG, Dawson-Hughes B, Sheehan P, Ware JH, Knowler WC, Aroda VR, Brodsky I, Ceglia L, Chadha C, Chatterjee R, Desouza C, Dolor R, Foreyt J, Fuss P, Ghazi A, Hsia DS, Johnson KC, Kashyap SR, Kim S, LeBlanc ES, Lewis MR, Liao E, Neff LM, Nelson J, O'Neil P, Park J, Peters A, Phillips LS, Pratley R, Raskin P, Rasouli N, Robbins D, Rosen C, Vickery EM, Staten M; D2d Research Group. Vitamin D Supplementation and Prevention of Type 2 Diabetes. N Engl J Med. 2019 Aug 8;381(6):520-530.
Kuhn, A, Park JY, Ghazi A, Aroda V. Intensifying Treatment Beyond Monotherapy in Type 2 Diabetes Mellitus: Where Do Newer Therapies Fit? Current Cardiology Reports. (2017) 19: 25.
Park JY, Chong AY, Cochran EK, Kleiner DE, Haller MJ, Schatz DA, Gorden P. Type 1 diabetes associated with acquired generalized lipodystrophy and insulin resistance: the effect of long-term leptin therapy. Journal of Clinical Endocrinology and Metabolism, 2008;93(1):26-31.
Guettier JM, Park JY, Cochran EK, Poitou C, Basdevant A, Meier M, Clément K, Magré J, Gorden P. Leptin therapy for partial lipodystrophy linked to a PPAR-gamma mutation. Clinical Endocrinology (Oxf). 2008;68(4):547-54.
Park JY, Javor ED, Cochran EK, DePaoli AM, Gorden P. Long-term efficacy of leptin replacement in patients with Dunnigan-type familial partial lipodystrophy. Metabolism, 2007; 56(4):508-16.
Park JY, Gavrilova O, Gorden P. The clinical utility of leptin therapy in metabolic dysfunction. Minerva Endocrinologica. 2006;31(2):125-31.
Gorden P, Park, JY. The clinical efficacy of the adipocyte-derived hormone leptin in metabolic diseases. Archives of Biochemistry and Physiology, 2006; 112(2):114-8.
